TICKERNERD
Menu
CPIXCPIXHealthcare · Drug Manufacturers - Specialty & Generic

CPIX Stock Forecast: Cumberland Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$4.87
−1.62% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 27 Oct 2026 — inside the top quartile.

Market cap
$65.2M
Ticker Nerd rank
80/ 100
Median analyst target
—
Analysts covering
1
Revenue$166K−98.5% y/y
Operating income−$3.2M
Net income−$4.3M
Free cash flow−$1.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−40.4%
1M
−36.9%
YTD
+45.9%
1Y
+76.0%
From 52W high
−45.7%
From 52W low
+205.6%
$1.59
$8.97
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CPIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cumberland Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
80/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Issuance
89
Quality
86
Momentum
80
Size
77
Value
67
Volatility
36
Revisions
25
Growth
22

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CPIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CPIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26CPIX

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Dec 2019B. RileyMaintainsBuy—
3 Dec 2019B. Riley SecuritiesMaintainsBuy$9.00 → $9.75
18 Nov 2019B. Riley FBRMaintainsBuy—
18 Nov 2019B. Riley SecuritiesMaintainsBuy—
17 Aug 2018B. Riley FBRMaintainsBuy—
17 Aug 2018B. Riley SecuritiesMaintainsBuy—
5 May 2018B. Riley FBRInitiatesBuy—
17 Apr 2018B. Riley FBRInitiatesBuy—
17 Apr 2018B. Riley SecuritiesInitiatesBuy—
10 Apr 2013UBSMaintainsNeutral—
12 Nov 2012UBSMaintainsNeutral—
9 Nov 2012Wells FargoDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CPIX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CPIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Cumberland Pharmaceuticals, Inc. returned +76.0% against +13.6% for the S&P 500, dividends included.

CPIX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300Jan 26Apr 26Jul 26Oct 26CPIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CPIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Cumberland Pharmaceuticals, Inc. (CPIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−25.8×

Cheaper than 97% of US stocks

Price / sales
1.7×

Cheaper than 56% of US stocks

Price / book
4.3×

Cheaper than 22% of US stocks

EV / EBITDA
59.9×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
−56.3%

Higher than 5% of US stocks

Earnings growth (YoY)
−98.5%

Higher than 2% of US stocks

Gross margin
78.8%

Higher than 90% of US stocks

Operating margin
−1898.7%

Higher than 4% of US stocks

Net margin
−24.6%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−14.4%

Higher than 34% of US stocks

Return on assets
−2.9%

Higher than 35% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cumberland Pharmaceuticals, Inc. (CPIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cumberland Pharmaceuticals, Inc. has a market value of $65.2M and an enterprise value of $65.7M.

  • Revenue in the twelve months to 30 June 2026: $31.3M. The latest quarter shrank 56.3% year on year.

  • Net income over the same four quarters: −$10.9M, a −35.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.71.

  • Free cash flow in the twelve months to 30 June 2026: −$1.2M.

  • Cumberland Pharmaceuticals, Inc. spent $71K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 15.0M.

  • Trailing P/E: −25.8×; forward P/E: 35.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cumberland Pharmaceuticals, Inc. employs 88 people — $355K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 27 Oct 2026

Data provided by Twelve Data

Peers

CPIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
CPIXCumberland Pharmaceuticals, Inc.$65.2M80
INCRInterCure Ltd.$64.8M—
CTORCitius Oncology, Inc.$56.8M41
TLPHTalphera, Inc.$54.6M39
ORGOOrganogenesis Holdings, Inc.$114.5M50
BGMBGM Group Ltd.$119.9M40
ZYBTZhengye Biotechnology Holding Ltd.$42.8M50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cumberland Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CPIX news & analysis

Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript

Seeking Alpha · 26 Oct 2026neutral

Seeking Alpha published a prepared-remarks transcript in which Cumberland Pharmaceuticals discusses a Duchenne cardiomyopathy NDA submission and its product development strategy.

Why it matters — The transcript provides CPIX watchers with information about the company’s regulatory plans and broader product development strategy.

Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy

MarketBeat · 26 Oct 2026positive

Cumberland Pharmaceuticals said it plans to begin a rolling New Drug Application submission for Dyscorban, its ifetroban candidate for Duchenne muscular dystrophy-associated cardiomyopathy, after the FDA granted its request for rolling review.

Why it matters — The development concerns the regulatory process for a CPIX drug candidate aimed at Duchenne-associated cardiomyopathy.

CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM

PRNewsWire · 26 Oct 2026positive

Cumberland Pharmaceuticals announced plans to file a new drug application for its ifetroban DMD program. The company described ifetroban as a product candidate being developed for cardiomyopathy associated with Duchenne muscular dystrophy.

Why it matters — The planned application filing is a development update for CPIX’s ifetroban program targeting a rare-disease complication.

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

PRNewsWire · 23 Oct 2026positive

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis. The company reported that ifetroban was well tolerated.

Why it matters — The update provides CPIX watchers with a clinical-trial and tolerability update on ifetroban for systemic sclerosis.

CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL

PRNewsWire · 23 Oct 2026neutral

Cumberland Pharmaceuticals confirmed it will provide an update on its ifetroban candidate, which is being developed as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy. The headline notes an updated webcast registration link for the program call.

Why it matters — CPIX watchers may be interested in the planned update on the development program for ifetroban.

FAQ

Frequently asked questions about CPIX stock

Is CPIX stock a buy right now?

Of the 1 analysts covering Cumberland Pharmaceuticals, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cumberland Pharmaceuticals, Inc. 80 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CPIX?

As at 27 Oct 2026, Cumberland Pharmaceuticals, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

What is the CPIX stock forecast for 2030?

No analyst covering Cumberland Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CPIX are extrapolating price history, which says nothing about the business.

How has CPIX stock performed over the past year?

Cumberland Pharmaceuticals, Inc. returned +76.0% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cumberland Pharmaceuticals, Inc. do?

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing branded prescription medicines for hospital acute care and other specialized treatment settings.

What is the latest news on CPIX?

The most recent item we track (Seeking Alpha, 26 Oct 2026): "Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript". Seeking Alpha published a prepared-remarks transcript in which Cumberland Pharmaceuticals discusses a Duchenne cardiomyopathy NDA submission and its product development strategy.

Company

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing branded prescription medicines for hospital acute care and other specialized treatment settings. Cumberland Pharmaceuticals markets a portfolio of approved products used in areas such as pain and fever management, nausea and vomiting prevention, constipation, hyponatremia, and certain bacterial infections. Its business centers on delivering therapies for physicians, hospitals, and patients who need targeted prescription treatments in areas where standard options may be limited or highly specialized. The company also operates in therapeutic markets including gastroenterology, oncology support, and critical care, reflecting its emphasis on products used in acute and hospital-based care. Cumberland Pharmaceuticals plays a niche role in the healthcare market by focusing on prescription medicines designed for specific clinical needs rather than broad consumer health products.

CEO Mr. A. J. Kazimi MBA · 88 employees · United States · https://www.cumberlandpharma.com